A Study of HS-20110 in Participants With Advanced Solid Tumors

Inclusion Criteria:

1. Males or females, aged ≥ 18 years.

2. Participants with pathologically (histologically or cytologically) confirmedadvanced solid tumors.

3. Participants have at least 1 target lesion other than CNS lesions according toRECIST 1.1.

Exclusion Criteria:

1. Participants have received or are receiving the following treatment:

2. Drug therapy targeting CDH17 (such as small molecule targeted drugs, monoclonalantibodies, bispecific antibodies, antibody-drug conjugates, or chimericantigen receptor T cells).

3. Anti-tumor drugs within 14 days prior to the first dose of study treatment; anyother IMPs or macromolecular anti-tumor drugs within 28 days prior to the firstdose of study treatment.

4. Local radiotherapy within 2 weeks prior to the first dose of study treatment;irradiation of more than 30% of bone marrow or extensive radiotherapy within 4weeks prior to the first dose of study treatment.

5. Major surgery within 4 weeks prior to the first dose of study treatment.

6. Participants previously treated with drugs that are moderate to stronginhibitors or moderate to strong inducers of cytochrome P450 (CYP) 3A4, stronginhibitors or strong inducers of CYP2D6, P-glycoprotein (P-gp), breast cancerresistance protein (BCRP) or drugs with a narrow therapeutic range that aresensitive substrates of P-gp or BCRP within 7 days prior to the first dose ofthe IMP. Participants who need to receive these drugs during the study periodshould also be excluded.

7. Current use of drugs known to prolong the QT interval or that may cause torsadede pointes. Participants who need to receive these drugs during the studyperiod should also be excluded.

8. Live vaccine or live-attenuated vaccine within 28 weeks prior to the firstdose.

9. Participants who have any Grade ≥ 2 residual toxicity according to CommonTerminology Criteria for Adverse Events (CTCAE, version 5.0) from prior therapies (except alopecia and residual neurotoxicity).

10. Inadequate bone marrow reserve or hepatic and renal functions.

11. Participants with a history of severe allergy (such as anaphylactic shock), previoussevere infusion reactions, or allergy to recombinant human or murine proteins.

12. Participants who are allergic to any component of HS-20110.